甘精胰岛素300U/mL的药代学和药效学特征

Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300U/mL

赛诺菲公司的新型胰岛素制剂“甘精胰岛素300U/mL”(简称:Gla-300)是近年来用于糖尿病临床管理的新型胰岛素制剂。大量药物代谢动力学和药物效应动力学的研究显示,Gla-300注射体积更小,却与Gla-100具有相同的降糖疗效。Gla-300具有更长、更恒定的药效时间,有较低的日内血糖变异性和较高的日间重复性,能够减少夜间低血糖和严重低血糖的发生。因此,Gla-300可作为1型和2型糖尿病患者基础胰岛素治疗的选择,对未接受胰岛素治疗或需要基础胰岛素剂量调整的患者同样具有潜在获益。本文对2017年5月发表在Clinical Pharmacokinetics杂志上的“甘精胰岛素300U/mL的临床药物代谢动力学和药物效应动力学特征”一文进行中文摘译。

Concentrated insulin analogs have recently been approved and are available for clinical use in the management of diabetes mellitus.One new product is insulin glargine 300(300U/mL,Sanofi),which is triple-concentrated agent to insulin glargine 100(100U/mL).Several clinical studies about pharmacokinetics and pharmacodynamics had revealed that Gla-300 had advantage over less injection volume and equally effective for glycemic control.Compared with insulin glargine 100,300 had a more constant and prolonged duration of action in treating type 1 and type 2 diabetes.Meanwhile,Gla-300 had a lower within-day variability and higher day-to-day reproducibility,lower rates of nocturnal and severe hypoglycemia than Gla-100.